Curing cancer through precision medicine is the paramount aim of the new wave of molecular and genomic therapies. Currently, whether patients with non-reproductive cancers are male or female according to their sex chromosomes is not adequately considered in patient standard of care. This is a matter of consequence because there is growing evidence that these cancer types generally initiate earlier and are associated with higher overall incidence and rates of death in males compared with females. Gender, in contrast to sex, refers to a chosen sexual identity. Hazardous lifestyle choices (notably tobacco smoking) differ in prevalence between genders, aligned with disproportionate cancer risk. These add to underlying genetic predisposition and influences of sex steroid hormones. Together, these factors affect metabolism, immunity and inflammation, and ultimately the fidelity of the genetic code. To accurately understand how human defences against cancer erode, it is crucial to establish the influence of sex. Our Perspective highlights evidence from basic and translational research indicating that including genetic sex considerations in treatments for patients with cancer will improve outcomes. It is now time to adopt the challenge of overhauling cancer medicine based on optimized treatment strategies for females and males.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Sex-biased molecular differences in lung adenocarcinoma are ethnic and smoking specific
BMC Pulmonary Medicine Open Access 24 March 2023
Sex differences in the diagnosis, treatment and prognosis of cancer: the rationale for an individualised approach
Clinical and Translational Oncology Open Access 18 February 2023
Deciphering genetic causes for sex differences in human health through drug metabolism and transporter genes
Nature Communications Open Access 12 January 2023
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
National Cancer Institute. SEER*Explorer. An interactive website for SEER cancer statistics https://seer.cancer.gov/explorer/ (2020).
Cook, M. B., McGlynn, K. A., Devesa, S. S., Freedman, N. D. & Anderson, W. F. Sex disparities in cancer mortality and survival. Cancer Epidemiol. Biomarkers Prev. 20, 1629–1637 (2011).
Clayton, J. A. & Collins, F. S. NIH to balance sex in cell and animal studies. Nature 509, 282–283 (2014).
Mauvais-Jarvis, F. et al. Sex and gender: modifiers of health, disease, and medicine. Lancet 396, 565–582 (2020).
Lopes-Ramos, C. M. et al. Sex differences in gene expression and regulatory networks across 29 human tissues. Cell Rep. 31, 107795 (2020).
Oliva, M. et al. The impact of sex on gene expression across human tissues. Science 369, eaba3066 (2020).
Clocchiatti, A., Cora, E., Zhang, Y. & Dotto, G. P. Sexual dimorphism in cancer. Nat. Rev. Cancer 16, 330–339 (2016).
Sun, T. et al. Sexually dimorphic RB inactivation underlies mesenchymal glioblastoma prevalence in males. J. Clin. Invest. 124, 4123–4133 (2014).
Fane, M. & Weeraratna, A. T. How the ageing microenvironment influences tumour progression. Nat. Rev. Cancer 20, 89–106 (2020).
Levine, A. J., Jenkins, N. A. & Copeland, N. G. The roles of initiating truncal mutations in human cancers: the order of mutations and tumor cell type matters. Cancer Cell 35, 10–15 (2019).
Podolskiy, D. I., Lobanov, A. V., Kryukov, G. V. & Gladyshev, V. N. Analysis of cancer genomes reveals basic features of human aging and its role in cancer development. Nat. Commun. 7, 12157 (2016).
Kim, J., Gosnell, J. E. & Roman, S. A. Geographic influences in the global rise of thyroid cancer. Nat. Rev. Endocrinol. 16, 17–29 (2020).
Levine, A. J. p53: 800 million years of evolution and 40 years of discovery. Nat. Rev. Cancer 20, 471–480 (2020).
Dominguez-Valentin, M. et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet. Med. 22, 15–25 (2020).
Lortet-Tieulent, J. et al. State-level cancer mortality attributable to cigarette smoking in the United States. JAMA Intern. Med. 176, 1792–1798 (2016).
Stone, T. W., McPherson, M. & Gail Darlington, L. Obesity and cancer: existing and new hypotheses for a causal connection. EBioMedicine 30, 14–28 (2018).
Barberio, A. M. et al. Central body fatness is a stronger predictor of cancer risk than overall body size. Nat. Commun. 10, 383 (2019).
Furman, D. et al. Chronic inflammation in the etiology of disease across the life span. Nat. Med. 25, 1822–1832 (2019).
Qian, S., Golubnitschaja, O. & Zhan, X. Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles. EPMA J. 10, 365–381 (2019).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Yuan, Y. et al. Comprehensive characterization of molecular differences in cancer between male and female patients. Cancer Cell 29, 711–722 (2016).
Aunan, J. R., Cho, W. C. & Soreide, K. The biology of aging and cancer: a brief overview of shared and divergent molecular hallmarks. Aging Dis. 8, 628–642 (2017).
Falzone, L., Salomone, S. & Libra, M. Evolution of cancer pharmacological treatments at the turn of the third millennium. Front. Pharmacol. 9, 1300 (2018).
Barros de Andrade, E. S. L. et al. Kinetics of Xist-induced gene silencing can be predicted from combinations of epigenetic and genomic features. Genome Res. 29, 1087–1099 (2019).
Delbridge, A. R. D. et al. Loss of p53 causes stochastic aberrant X-chromosome inactivation and female-specific neural tube defects. Cell Rep. 27, 442–454.e5 (2019).
Aken, B. L. et al. The Ensembl gene annotation system. Database https://doi.org/10.1093/database/baw093 (2016).
Tukiainen, T. et al. Landscape of X chromosome inactivation across human tissues. Nature 550, 244–248 (2017).
Peeters, S. B., Cotton, A. M. & Brown, C. J. Variable escape from X-chromosome inactivation: identifying factors that tip the scales towards expression. Bioessays 36, 746–756 (2014).
Migeon, B. R. X-linked diseases: susceptible females. Genet. Med. 22, 1156–1174 (2020).
Di Palo, A. et al. What microRNAs could tell us about the human X chromosome. Cell Mol Life Sci. 77, 4069–4080 (2020).
Care, A. et al. Sex disparity in cancer: roles of microRNAs and related functional players. Cell Death Differ. 25, 477–485 (2018).
Chamekh, M. & Casimir, G. Editorial: sexual dimorphism of the immune inflammatory response in infectious and non-infectious diseases. Front. Immunol. 10, 107 (2019).
Spolarics, Z., Pena, G., Qin, Y., Donnelly, R. J. & Livingston, D. H. Inherent X-linked genetic variability and cellular mosaicism unique to females contribute to sex-related differences in the innate immune response. Front. Immunol. 8, 1455 (2017).
Chaligne, R. & Heard, E. X-chromosome inactivation in development and cancer. FEBS Lett. 588, 2514–2522 (2014).
Wang, D. et al. Abnormal X chromosome inactivation and tumor development. Cell Mol. Life Sci. 77, 2949–2958 (2020).
van Kempen, L. C. et al. The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. Sci. Transl Med. 8, 369ra177 (2016).
Andricovich, J. et al. Loss of KDM6A activates super-enhancers to induce gender-specific squamous-like pancreatic cancer and confers sensitivity to BET inhibitors. Cancer Cell 33, 512–526.e8 (2018).
Dunford, A. et al. Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Nat. Genet. 49, 10–16 (2017).
Yildirim, E. et al. Xist RNA is a potent suppressor of hematologic cancer in mice. Cell 152, 727–742 (2013).
Yang, L., Yildirim, E., Kirby, J. E., Press, W. & Lee, J. T. Widespread organ tolerance to Xist loss and X reactivation except under chronic stress in the gut. Proc. Natl Acad. Sci. USA 117, 4262–4272 (2020).
Ren, W. et al. Disruption of ATRX–RNA interactions uncovers roles in ATRX localization and PRC2 function. Nat. Commun. 11, 2219 (2020).
Haupt, S. et al. Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network. Nat. Commun. 10, 5385 (2019).
Sun, T., Plutynski, A., Ward, S. & Rubin, J. B. An integrative view on sex differences in brain tumors. Cell Mol. Life Sci. 72, 3323–3342 (2015).
Emran, A. A. et al. Study of the female sex survival advantage in melanoma — a focus on X-linked epigenetic regulators and immune responses in two cohorts. Cancers 12, 2082 (2020).
George, S. L. et al. Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma. EBioMedicine 59, 102971 (2020).
Ler, L. D. et al. Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. Sci. Transl Med. 9, eaai8312 (2017).
Meester, I. et al. SeXY chromosomes and the immune system: reflections after a comparative study. Biol. Sex. Differ. 11, 3 (2020).
Caceres, A., Jene, A., Esko, T., Perez-Jurado, L. A. & Gonzalez, J. R. Extreme down-regulation of chromosome Y and cancer risk in men. J. Natl Cancer Inst. 112, 913–920 (2020).
Hollows, R. et al. Association between loss of Y chromosome and poor prognosis in male head and neck squamous cell carcinoma. Head Neck 41, 993–1006 (2019).
Loftfield, E. et al. Mosaic Y loss is moderately associated with solid tumor risk. Cancer Res. 79, 461–466 (2019).
Brown, D. W., Machiela, M. J. & Why, Y. Down-regulation of chromosome Y genes potentially contributes to elevated cancer risk. J. Natl Cancer Inst. 112, 871–872 (2020).
Walport, L. J. et al. Human UTY(KDM6C) is a male-specific N-methyl lysyl demethylase. J. Biol. Chem. 289, 18302–18313 (2014).
Gozdecka, M. et al. UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs. Nat. Genet. 50, 883–894 (2018).
Sarne, V. et al. Promoter methylation of selected genes in non-small-cell lung cancer patients and cell lines. Int. J. Mol. Sci. 21, 4595 (2020).
Iranzo, J., Martincorena, I. & Koonin, E. V. Cancer-mutation network and the number and specificity of driver mutations. Proc. Natl Acad. Sci. USA 115, E6010–E6019 (2018).
Li, C. H., Haider, S., Shiah, Y. J., Thai, K. & Boutros, P. C. Sex differences in cancer driver genes and biomarkers. Cancer Res. 78, 5527–5537 (2018).
Li, C. H. et al. Sex differences in oncogenic mutational processes. Nat. Commun. 11, 4330 (2020).
Lopes-Ramos, C. M. et al. Gene regulatory network analysis identifies sex-linked differences in colon cancer drug metabolism. Cancer Res. 78, 5538–5547 (2018).
Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94–101 (2020).
Jung, Y. S. & Park, J. I. Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex. Exp. Mol. Med. 52, 183–191 (2020).
Kobrinski, D. A., Yang, H. & Kittaneh, M. BAP1: role in carcinogenesis and clinical implications. Transl Lung Cancer Res. 9, S60–S66 (2020).
Gillette, M. A. et al. Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma. Cell 182, 200–225.e35 (2020).
Tsuji, T. et al. YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation. Nat. Commun. 11, 74 (2020).
Pinto, J. A. et al. Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy? ESMO Open 3, e000344 (2018).
Soussi, T. & Wiman, K. G. TP53: an oncogene in disguise. Cell Death Differ. 22, 1239–1249 (2015).
Jia, P. & Zhao, Z. Characterization of tumor-suppressor gene inactivation events in 33 cancer types. Cell Rep. 26, 496–506.e3 (2019).
Levine, A. J. Targeting therapies for the p53 protein in cancer treatments. Annu. Rev. Cancer Biol. 3, 21–34 (2019).
Donehower, L. A. et al. Integrated analysis of TP53 gene and pathway alterations in The Cancer Genome Atlas. Cell Rep. 28, 1370–1384.e5 (2019).
Williams, A. B. & Schumacher, B. p53 in the DNA-damage–repair process. Cold Spring Harb. Perspect. Med. 6, a026070 (2016).
Cancer Genome Atlas Research Network. et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113–1120 (2013).
Olive, K. P. et al. Mutant p53 gain of function in two mouse models of Li–Fraumeni syndrome. Cell 119, 847–860 (2004).
Zore, T., Palafox, M. & Reue, K. Sex differences in obesity, lipid metabolism, and inflammation — a role for the sex chromosomes? Mol. Metab. 15, 35–44 (2018).
Clegg, D. J. & Mauvais-Jarvis, F. An integrated view of sex differences in metabolic physiology and disease. Mol. Metab. 15, 1–2 (2018).
Liberti, M. V. & Locasale, J. W. The Warburg effect: how does it benefit cancer cells? Trends Biochem. Sci. 41, 211–218 (2016).
Keramida, G. & Peters, A. M. Fasting hepatic glucose uptake is higher in men than women. Physiol. Rep. 5, e13174 (2017).
Han, H. et al. Blood glucose concentration and risk of liver cancer: systematic review and meta-analysis of prospective studies. Oncotarget 8, 50164–50173 (2017).
Vulcan, A., Manjer, J. & Ohlsson, B. High blood glucose levels are associated with higher risk of colon cancer in men: a cohort study. BMC Cancer 17, 842 (2017).
Wang, J. et al. Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis. Oncotarget 8, 16875–16886 (2017).
Schwartzenberg-Bar-Yoseph, F., Armoni, M. & Karnieli, E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 64, 2627–2633 (2004).
Tan, Z., Yang, C., Zhang, X., Zheng, P. & Shen, W. Expression of glucose transporter 1 and prognosis in non-small cell lung cancer: a pooled analysis of 1665 patients. Oncotarget 8, 60954–60961 (2017).
Zhang, C. et al. Tumour-associated mutant p53 drives the Warburg effect. Nat. Commun. 4, 2935 (2013).
Rodriguez, O. C. et al. Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle 11, 4436–4446 (2012).
Labuschagne, C. F., Zani, F. & Vousden, K. H. Control of metabolism by p53—cancer and beyond. Biochim. Biophys. Acta Rev. Cancer 1870, 32–42 (2018).
Jiang, P. et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat. Cell Biol. 13, 310–316 (2011).
Wang, Y., Xiao, J., Zhao, Y., Du, S. & Du, J. Effect of metformin on the mortality of colorectal cancer patients with T2DM: meta-analysis of sex differences. Int. J. Colorectal Dis. 35, 827–835 (2020).
Mele, L. et al. A new inhibitor of glucose-6-phosphate dehydrogenase blocks pentose phosphate pathway and suppresses malignant proliferation and metastasis in vivo. Cell Death Dis. 9, 572 (2018).
Li, W. et al. Effects of hyperglycemia on the progression of tumor diseases. J. Exp. Clin. Cancer Res. 38, 327 (2019).
Mueller, F. et al. Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer Chemother. Pharmacol. 71, 361–370 (2013).
Hu, X., Chao, M. & Wu, H. Central role of lactate and proton in cancer cell resistance to glucose deprivation and its clinical translation. Signal. Transduct. Target. Ther. 2, 16047 (2017).
de la Cruz-Lopez, K. G., Castro-Munoz, L. J., Reyes-Hernandez, D. O., Garcia-Carranca, A. & Manzo-Merino, J. Lactate in the regulation of tumor microenvironment and therapeutic approaches. Front. Oncol. 9, 1143 (2019).
Ippolito, J. E., Yim, A. K., Luo, J., Chinnaiyan, P. & Rubin, J. B. Sexual dimorphism in glioma glycolysis underlies sex differences in survival. JCI Insight 2, e92142 (2017).
Cao, J., Ng, M. & Felmlee, M. A. Sex hormones regulate rat hepatic monocarboxylate transporter expression and membrane trafficking. J. Pharm. Pharm Sci. 20, 435–444 (2017).
Pinheiro, C. et al. The metabolic microenvironment of melanomas: prognostic value of MCT1 and MCT4. Cell Cycle 15, 1462–1470 (2016).
Renner, K. et al. Restricting glycolysis preserves T cell effector functions and augments checkpoint therapy. Cell Rep. 29, 135–150.e9 (2019).
Beloueche-Babari, M. et al. Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration. Br. J. Cancer 122, 895–903 (2020).
Hendriks, S. H. et al. Association between body mass index and obesity-related cancer risk in men and women with type 2 diabetes in primary care in the Netherlands: a cohort study (ZODIAC-56). BMJ Open 8, e018859 (2018).
O’Flanagan, C. H., Smith, L. A., McDonell, S. B. & Hursting, S. D. When less may be more: calorie restriction and response to cancer therapy. BMC Med. 15, 106 (2017).
Karczewski, J. et al. Obesity and the risk of gastrointestinal cancers. Dig. Dis. Sci. 64, 2740–2749 (2019).
Mancuso, P. The role of adipokines in chronic inflammation. Immunotargets Ther. 5, 47–56 (2016).
Wlodarczyk, M. & Nowicka, G. Obesity, DNA damage, and development of obesity-related diseases. Int. J. Mol. Sci. 20, 1146 (2019).
Kern, L. et al. Obesity-induced TNFα and IL-6 signaling: the missing link between obesity and inflammation-driven liver and colorectal cancers. Cancers 11, 24 (2018).
Chia, V. M. et al. Leptin concentrations, leptin receptor polymorphisms, and colorectal adenoma risk. Cancer Epidemiol. Biomarkers Prev. 16, 2697–2703 (2007).
Starling, S. New therapeutic promise for leptin. Nat. Rev. Endocrinol. 15, 625 (2019).
Orthofer, M. et al. Identification of ALK in thinness. Cell 181, 1246–1262.e22 (2020).
Roberts, D. L., Dive, C. & Renehan, A. G. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu. Rev. Med. 61, 301–316 (2010).
Manieri, E. et al. Adiponectin accounts for gender differences in hepatocellular carcinoma incidence. J. Exp. Med. 216, 1108–1119 (2019).
Di Zazzo, E. et al. Adiponectin as link factor between adipose tissue and cancer. Int. J. Mol. Sci. 20, 839 (2019).
He, L. & Wondisford, F. E. Metformin action: concentrations matter. Cell Metab. 21, 159–162 (2015).
Qin, Y. et al. An obesity-associated gut microbiome reprograms the intestinal epigenome and leads to altered colonic gene expression. Genome Biol. 19, 7 (2018).
Holloway, M. G., Miles, G. D., Dombkowski, A. A. & Waxman, D. J. Liver-specific hepatocyte nuclear factor-4α deficiency: greater impact on gene expression in male than in female mouse liver. Mol. Endocrinol. 22, 1274–1286 (2008).
Baars, A. et al. Sex differences in lipid metabolism are affected by presence of the gut microbiota. Sci. Rep. 8, 13426 (2018).
Almeida, A. et al. A new genomic blueprint of the human gut microbiota. Nature 568, 499–504 (2019).
Bana, B. & Cabreiro, F. The microbiome and aging. Annu. Rev. Genet. 53, 239–261 (2019).
Vemuri, R. et al. The microgenderome revealed: sex differences in bidirectional interactions between the microbiota, hormones, immunity and disease susceptibility. Semin. Immunopathol. 41, 265–275 (2019).
Ma, Z. S. & Li, W. How and why men and women differ in their microbiomes: medical ecology and network analyses of the microgenderome. Adv. Sci. 6, 1902054 (2019).
Kim, Y. S., Unno, T., Kim, B. Y. & Park, M. S. Sex differences in gut microbiota. World J. Mens Health 38, 48–60 (2020).
Santos-Marcos, J. A. et al. Sex differences in the gut microbiota as potential determinants of gender predisposition to disease. Mol. Nutr. Food Res. 63, e1800870 (2019).
de la Cuesta-Zuluaga, J. et al. Age- and sex-dependent patterns of gut microbial diversity in human adults. mSystems 4, e00261-19 (2019).
Weger, B. D. et al. The mouse microbiome is required for sex-specific diurnal rhythms of gene expression and metabolism. Cell Metab. 29, 362–382.e8 (2019).
Panda, S. The arrival of circadian medicine. Nat. Rev. Endocrinol. 15, 67–69 (2019).
Ma, W. et al. Gut microbiota shapes the efficiency of cancer therapy. Front. Microbiol. 10, 1050 (2019).
Cai, Y. et al. Sex differences in colon cancer metabolism reveal a novel subphenotype. Sci. Rep. 10, 4905 (2020).
Krall, A. S., Xu, S., Graeber, T. G., Braas, D. & Christofk, H. R. Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor. Nat. Commun. 7, 11457 (2016).
Schmuck, R. et al. Gender comparison of clinical, histopathological, therapeutic and outcome factors in 185,967 colon cancer patients. Langenbecks Arch. Surg. 405, 71–80 (2020).
Yang, Y. et al. Gender differences in colorectal cancer survival: a meta-analysis. Int. J. Cancer 141, 1942–1949 (2017).
Gubbels Bupp, M. R., Potluri, T., Fink, A. L. & Klein, S. L. The confluence of sex hormones and aging on immunity. Front. Immunol. 9, 1269 (2018).
Klein, S. L. & Flanagan, K. L. Sex differences in immune responses. Nat. Rev. Immunol. 16, 626–638 (2016).
Scully, E. P., Haverfield, J., Ursin, R. L., Tannenbaum, C. & Klein, S. L. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat. Rev. Immunol. 20, 442–447 (2020).
Schurz, H. et al. The X chromosome and sex-specific effects in infectious disease susceptibility. Hum. Genomics 13, 2 (2019).
Taniguchi, K. & Karin, M. NF-κB, inflammation, immunity and cancer: coming of age. Nat. Rev. Immunol. 18, 309–324 (2018).
Marquez, E. J. et al. Sexual-dimorphism in human immune system aging. Nat. Commun. 11, 751 (2020).
Ley, K. M1 means kill; M2 means heal. J. Immunol. 199, 2191–2193 (2017).
Lin, Y., Xu, J. & Lan, H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J. Hematol. Oncol. 12, 76 (2019).
Brown, J. M., Recht, L. & Strober, S. The promise of targeting macrophages in cancer therapy. Clin. Cancer Res. 23, 3241–3250 (2017).
Li, L. et al. TLR8-mediated metabolic control of human Treg function: a mechanistic target for cancer immunotherapy. Cell Metab. 29, 103–123.e5 (2019).
Ono, M. Control of regulatory T-cell differentiation and function by T-cell receptor signalling and Foxp3 transcription factor complexes. Immunology 160, 24–37 (2020).
Vasanthakumar, A. et al. Sex-specific adipose tissue imprinting of regulatory T cells. Nature 579, 581–585 (2020).
Huang, L., Xu, H. & Peng, G. TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy. Cell Mol. Immunol. 15, 428–437 (2018).
de Martel, C., Georges, D., Bray, F., Ferlay, J. & Clifford, G. M. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob. Health 8, e180–e190 (2020).
Guven-Maiorov, E., Tsai, C. J. & Nussinov, R. Oncoviruses can drive cancer by rewiring signaling pathways through interface mimicry. Front. Oncol. 9, 1236 (2019).
Te Marvelde, L. et al. Epidemiology of sepsis in cancer patients in Victoria, Australia: a population-based study using linked data. Aust. N. Z. J. Public Health 44, 53–58 (2020).
Wisnivesky, J. P. & Halm, E. A. Sex differences in lung cancer survival: do tumors behave differently in elderly women? J. Clin. Oncol. 25, 1705–1712 (2007).
Morgese, F. et al. Gender differences and outcomes in melanoma patients. Oncol. Ther. 8, 103–114 (2020).
Roers, A., Hiller, B. & Hornung, V. Recognition of endogenous nucleic acids by the innate immune system. Immunity 44, 739–754 (2016).
Souyris, M. et al. TLR7 escapes X chromosome inactivation in immune cells. Sci. Immunol. 3, eaap8855 (2018).
Roach, J. C. et al. The evolution of vertebrate Toll-like receptors. Proc. Natl Acad. Sci. USA 102, 9577–9582 (2005).
Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11, 373–384 (2010).
Vierbuchen, T., Stein, K. & Heine, H. RNA is taking its toll: impact of RNA-specific Toll-like receptors on health and disease. Allergy 74, 223–235 (2019).
Zhang, Z. et al. Structural analyses of Toll-like receptor 7 reveal detailed RNA sequence specificity and recognition mechanism of agonistic ligands. Cell Rep. 25, 3371–3381.e5 (2018).
Mui, U. N., Haley, C. T. & Tyring, S. K. Viral oncology: molecular biology and pathogenesis. J. Clin. Med. 6, 111 (2017).
Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 36–49 (2014).
Berghofer, B. et al. TLR7 ligands induce higher IFN-α production in females. J. Immunol. 177, 2088–2096 (2006).
Oshiumi, H., Sakai, K., Matsumoto, M. & Seya, T. DEAD/H BOX 3 (DDX3) helicase binds the RIG-I adaptor IPS-1 to up-regulate IFN-β-inducing potential. Eur. J. Immunol. 40, 940–948 (2010).
Phung, B. et al. The X-linked DDX3X RNA helicase dictates translation reprogramming and metastasis in melanoma. Cell Rep. 27, 3573–3586.e7 (2019).
Libert, C., Dejager, L. & Pinheiro, I. The X chromosome in immune functions: when a chromosome makes the difference. Nat. Rev. Immunol. 10, 594–604 (2010).
Klein, S. L. & Morgan, R. The impact of sex and gender on immunotherapy outcomes. Biol. Sex. Differ. 11, 24 (2020).
Golden, L. C. et al. Parent-of-origin differences in DNA methylation of X chromosome genes in T lymphocytes. Proc Natl Acad Sci USA 116, 26779–26787 (2019).
Menendez, D. et al. p53-responsive TLR8 SNP enhances human innate immune response to respiratory syncytial virus. J. Clin. Invest. 129, 4875–4884 (2019).
Wang, P. F., Song, H. F., Zhang, Q. & Yan, C. X. Pan-cancer immunogenomic analyses reveal sex disparity in the efficacy of cancer immunotherapy. Eur. J. Cancer 126, 136–138 (2020).
Freudenstein, D. et al. TP53 status, patient sex, and the immune response as determinants of lung cancer patient survival. Cancers 12, 1535 (2020).
Kruger, S. et al. Advances in cancer immunotherapy 2019 — latest trends. J. Exp. Clin. Cancer Res. 38, 268 (2019).
Castro, A. et al. Strength of immune selection in tumors varies with sex and age. Nat. Commun. 11, 4128 (2020).
Ye, Y. et al. Sex-associated molecular differences for cancer immunotherapy. Nat. Commun. 11, 1779 (2020).
Badami, S. et al. Clinical and molecular characteristics associated with survival in advanced melanoma treated with checkpoint inhibitors. J. Oncol. 2018, 6279871 (2018).
Conforti, F. et al. Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis. J. Natl Cancer Inst. 111, 772–781 (2019).
Wallis, C. J. D. et al. Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: a systematic review and meta-analysis. JAMA Oncol. 5, 529–536 (2019).
Murthy, V. H., Krumholz, H. M. & Gross, C. P. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291, 2720–2726 (2004).
Okyar, A. et al. Sex-, feeding-, and circadian time-dependency of P-glycoprotein expression and activity — implications for mechanistic pharmacokinetics modeling. Sci. Rep. 9, 10505 (2019).
Gopalakrishnan, V., Helmink, B. A., Spencer, C. N., Reuben, A. & Wargo, J. A. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell 33, 570–580 (2018).
Gong, J. et al. The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies. Clin. Transl Med. 8, 9 (2019).
Schroder, W. et al. Gender differences in antibiotic prescribing in the community: a systematic review and meta-analysis. J. Antimicrob. Chemother. 71, 1800–1806 (2016).
Pinato, D. J. et al. Antibiotic therapy and outcome from immune-checkpoint inhibitors. J. Immunother. Cancer 7, 287 (2019).
Tibbs, T. N., Lopez, L. R. & Arthur, J. C. The influence of the microbiota on immune development, chronic inflammation, and cancer in the context of aging. Microb. Cell 6, 324–334 (2019).
De Courcy, L., Bezak, E. & Marcu, L. G. Gender-dependent radiotherapy: the next step in personalised medicine? Crit. Rev. Oncol. Hematol. 147, 102881 (2020).
Wagner, A. D. et al. Gender medicine and oncology: report and consensus of an ESMO workshop. Ann. Oncol. 30, 1914–1924 (2019).
Davidson, M. et al. Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: a pooled analysis of four randomised trials. Eur. J. Cancer 121, 40–47 (2019).
Wheatley-Price, P. et al. The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials. J. Thorac. Oncol. 5, 640–648 (2010).
Yang, W. et al. Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data. Sci. Transl Med. 11, eaao5253 (2019).
Ozdemir, B. C., Csajka, C., Dotto, G. P. & Wagner, A. D. Sex differences in efficacy and toxicity of systemic treatments: an undervalued issue in the era of precision oncology. J. Clin. Oncol. 36, 2680–2683 (2018).
Kim, H. I., Lim, H. & Moon, A. Sex differences in cancer: epidemiology, genetics and therapy. Biomol. Ther. 26, 335–342 (2018).
Yang, L. et al. Sex differences in the expression of drug-metabolizing and transporter genes in human liver. J. Drug. Metab. Toxicol. 3, 1000119 (2012).
Joseph, S. et al. Expression of drug transporters in human kidney: impact of sex, age, and ethnicity. Biol. Sex. Differ. 6, 4 (2015).
Bayik, D. et al. Myeloid-derived suppressor cell subsets drive glioblastoma growth in a sex-specific manner. Cancer Discov. 10, 1210–1225 (2020).
Wagner, A. D. Sex differences in cancer chemotherapy effects, and why we need to reconsider BSA-based dosing of chemotherapy. ESMO Open 5, e000770 (2020).
Greenberg, M. V. C. & Bourc’his, D. The diverse roles of DNA methylation in mammalian development and disease. Nat. Rev. Mol. Cell Biol. 20, 590–607 (2019).
Kolberg, L., Raudvere, U., Kuzmin, I., Vilo, J. & Peterson, H. gprofiler2 — an R package for gene list functional enrichment analysis and namespace conversion toolset g:profiler. F1000Res https://doi.org/10.12688/f1000research.24956.2 (2020).
Goodwin, M. L. et al. Lactate and cancer: a “lactatic” perspective on spinal tumor metabolism (part 1). Ann. Transl Med. 7, 220 (2019).
Sikora, M. J., Johnson, M. D., Lee, A. V. & Oesterreich, S. Endocrine response phenotypes are altered by charcoal-stripped serum variability. Endocrinology 157, 3760–3766 (2016).
De Souza Santos, R., Frank, A. P., Palmer, B. F. & Clegg, D. J. Sex and media: considerations for cell culture studies. ALTEX 35, 435–440 (2018).
Bittner, G. D., Yang, C. Z. & Stoner, M. A. Estrogenic chemicals often leach from BPA-free plastic products that are replacements for BPA-containing polycarbonate products. Environ. Health 13, 41 (2014).
Austad, S. N. & Fischer, K. E. Sex differences in lifespan. Cell Metab. 23, 1022–1033 (2016).
Menendez, D. et al. The Toll-like receptor gene family is integrated into human DNA damage and p53 networks. PLoS Genet. 7, e1001360 (2011).
Norheim, F. et al. Gene-by-sex interactions in mitochondrial functions and cardio-metabolic traits. Cell Metab. 29, 932–949.e4 (2019).
[No authors listed] Accounting for sex in the genome. Nat. Med. 23, 1243 (2017).
Anderson, K., Canadas-Garre, M., Chambers, R., Maxwell, A. P. & McKnight, A. J. The challenges of chromosome Y analysis and the implications for chronic kidney disease. Front. Genet. 10, 781 (2019).
Duncan, C. G. et al. Dosage compensation and DNA methylation landscape of the X chromosome in mouse liver. Sci. Rep. 8, 10138 (2018).
Garieri, M. et al. Extensive cellular heterogeneity of X inactivation revealed by single-cell allele-specific expression in human fibroblasts. Proc. Natl Acad. Sci. USA 115, 13015–13020 (2018).
Cotton, A. M. et al. Landscape of DNA methylation on the X chromosome reflects CpG density, functional chromatin state and X-chromosome inactivation. Hum. Mol. Genet. 24, 1528–1539 (2015).
Olney, K. C., Brotman, S. M., Andrews, J. P., Valverde-Vesling, V. A. & Wilson, M. A. Reference genome and transcriptome informed by the sex chromosome complement of the sample increase ability to detect sex differences in gene expression from RNA-seq data. Biol. Sex. Differ. 11, 42 (2020).
Rubin, J. B. et al. Sex differences in cancer mechanisms. Biol. Sex. Differ. 11, 17 (2020).
The authors thank C. Litchfield for undertaking the analyses for Figs 1 and 3 and also for Supplementary Tables 1 and 2. The Haupt laboratory acknowledges funding from the Sister Institution Network Fund (SINF), MD Anderson–Peter MacCallum Cancer Centre and Peter MacCallum Foundation. S.L.K. was supported in part by the National Institutes of Health (NIH) Specialized Center of Research Excellence (U54AG062333) and NIH Center of Excellence in Influenza Research and Surveillance (HHSN272201400007C). Work in the Rubin laboratory is supported by the NIH (R01 CA174737 to J.B.R.), The Children’s Discovery Institute of Washington University, Prayers for Maria Foundation, St Louis Children’s Hospital Foundation, Barnes-Jewish Hospital Foundation, Barnard Research Funds, Joshua’s Great Things Foundation and The American Brain Tumor Association.
The authors declare no competing interests.
Peer review information
Nature Reviews Cancer thanks G. P. Dotto, J. Feunteun and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Bi-allelic gene expression
Expression from the two chromosomal copies (alleles) of a gene, as opposed to expression from one chromosomal copy (mono-allelic expression).
- COMPASS-like complex
(Complex of proteins associated with Set1). A conserved complex of core proteins that function with specific methyltransferases to catalyse methylation of histone H3 at K4 or demethylation, for example in the context of KDM6A, controlling transcriptional regulation.
- Immune checkpoint
A receptor–ligand molecule whose normal function is to regulate the magnitude and duration of immune responses that can be exploited by cancers to prevent anticancer T cell responses. Checkpoint inhibitors block these interactions, thereby restoring the ability of T cells to attack cancer cells.
- Mosaic expression
Expression, in females, of different copies of the X chromosome in different cells. This results in a mosaic pattern of expression of different X-linked genes or forms of X-linked genes within a tissue of an individual.
- M1 and M2
Two classes of macrophages with different functions. M1 macrophages kill cancer cells and infectious agents, whereas M2 macrophages heal wounds. In many cancer types, M1 gene expression signatures correspond to a favourable outcome, whereas M2 signatures align with poor outcomes.
- Pattern recognition receptor
A protein that engages signatures of pathogens or damages and primes the innate immune response. In the instance of Toll-like receptor 7 (TLR7) and TLR8 these proteins function as receptors for single-stranded RNA molecules, as relevant to triggering innate immunity against viral infections.
An extreme form of mosaicism in which either the maternal or paternal X chromosome is preferentially active.
- Sporadic cancers
Cancers that arise spontaneously from genomic damage that is acquired, in contrast to familial cancers associated with inherited genetic alterations that are predisposing.
- Truncal mutations
Mutations that occur in the cell lineage that gave rise to the clonal tumour. These are also called clonal mutations.
- X pseudoautosomal regions
The short regions at the end of the X and Y chromosomes that share homology. These regions are important for the pairing and segregation of the X and Y chromosomes during meiosis in males. The behaviour of these regions is similar to that of autosomes.
Rights and permissions
About this article
Cite this article
Haupt, S., Caramia, F., Klein, S.L. et al. Sex disparities matter in cancer development and therapy. Nat Rev Cancer 21, 393–407 (2021). https://doi.org/10.1038/s41568-021-00348-y
This article is cited by
Sex-biased molecular differences in lung adenocarcinoma are ethnic and smoking specific
BMC Pulmonary Medicine (2023)
Deciphering genetic causes for sex differences in human health through drug metabolism and transporter genes
Nature Communications (2023)
Geschlechtsspezifische Unterschiede in gastroenterologischen Erkrankungen
Die Innere Medizin (2023)
Sex differences in the diagnosis, treatment and prognosis of cancer: the rationale for an individualised approach
Clinical and Translational Oncology (2023)
The spatiotemporal dynamics of lung cancer: 30-year trends of epidemiology across 204 countries and territories
BMC Public Health (2022)